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1. Introduction
1.1. Epidermolysis bullosa
Epidermolysis bullosa (EB) is a genetically and clinically variable disease characterized by blis‐
ter formation and erosions of the skin and mucous membranes after minor trauma [1]. The in‐
heritance of the affected genes can occur in a dominant or recessive way depending on the
subform of the disease. In general, epidermolysis bullosa is caused by mutations in genes en‐
coding structural proteins within the basal membrane zone of the skin. Absence or functional
loss of one of these proteins results in a lack of stability of the microarchitecture of the connec‐
tion between dermis and epidermis leading to a loss of coherence [1]. The basement membrane
between the dermis and the epidermis is a complex membrane produced by basal keratino‐
cytes and dermal fibroblasts that acts as mechanical support for the connection of both skin lay‐
ers.  The  basal  membrane  also  regulates  the  metabolic  exchange  between  the  two  skin
compartments [2]. Up to date, there are at least 15 genes associated with EB causing different
forms of the disease. Numerous mutations in these genes that encode for structural proteins
within keratinocytes or within mucocutaneous basement membranes have been identified up
to now [1].
Mutations in the genes, encoding for the keratins 5 and 14 and plectin, lead to epidermolysis
bullosa simplex (EBS) characterized by the cytolysis within basal keratinocytes. Junctional epi‐
dermolysis bullosa (JEB) is caused by the absence or loss of function of laminin-332, type XVII
collagen or integrin-β4. JEB is a severe EB form and is characterized by the separation of the
skin within the lamina lucida. Mutations in type VII collagen (encoded by COL7A1) lead to the
dystrophic form of epidermolysis bullosa, characterized by skin separation below the lamina
densa. The severity and clinical manifestation of the disease depend on the mutation type (mis‐
sense mutation, nonsense mutation, splice site mutations, deletion or insertion), the mode of
inheritance and the localization of the mutation within the gene. Due to this fact, diagnosis,
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course of disease and therapy vary significantly depending on the present EB subform [3]. Blis‐
ter formation can be restricted to the soles of the feet or occur generalized. Severe systemic com‐
plications and extracutaneous manifestations including blistering and erosions of the cornea
and mucosal tissues, stenoses or strictures of respiratory, gastrointestinal and urogenital tracts,
pylorus atresia, muscular dystrophy and skin cancer are certain complications associated with
different EB subtypes [1]. So far over 30 distinctive subtypes have been described and classified
in a system, which was recently revised [4]. See Table 1.
A: Classification scheme for the major EB subtypes
Major EB type Major EB subtypes Affected proteins
EB simplex (EBS) Suprabasal EBS plakophilin-1, desmoplakin;
others?
Basal EBS keratins 5 & 14; plectin,
α6β4 integrin, BPAG1
Junctional EB (JEB) JEB, Herlitz (JEB-H) laminin-332, (laminin-5)
JEB, other laminin-332, type XVII collagen
α6β4 integrin, α3 integrin
Dystrophic EB (DEB) Dominant DEB (DDEB) type VII collagen
Recessive DEB (RDEB) type VII collagen
Kindler syndrome kindlin-1
B: Classification scheme for all known EB simplex subtypes
Major types EBS subtypes Affected proteins
EBS suprabasal lethal acantholytic EB desmoplakin
plakophilin deficiency plakophilin-1
EBS superficialis ?
EBS basal EBS, localized (EBS-loc)a K5, K14
EBS, Dowling Meara (EBS-DM) K5, K14
EBS, other generalized (EBS,gen-nonDM)b K5, K14, BPAG1
EBS with mottled pigmentation(EBS-MP) K5
EBS with muscular dystrophy (EBS-MD) plectin
EBS with pylorus atresia (EBS-PA) plectin, α6β4 integrin
EBS, autosomal recessive (EBS-AR) K14
EBS, ogna (EBS-Og) plectin
EBS, migratory circinate (EBS-migr) K5
(rare variants in italics)
a Previously called EBS, Weber-Cockayne
b Includes patients previously classified as EBS-Koebner
C: Classification scheme for all known junctional subtypes
Major JEB subtype Subtypes Affected proteins
JEB, Herlitz (JEB-H) laminin-332
JEB, other (JEB-O) JEB, non-Herlitz, generalized (JEB-nH gen)a laminin-332, type XVII collagen
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JEB, non-Herlitz localized (JEB-nH loc) typeXVII collagen
JEB with pyloric atresia (JEB-PA) α6β4 integrin
JEB, inversa (JEB-I) laminin-332
JEB, late onset (JEB-lo)b
LOC syndrome (laryngo-onycho-cutaneous syndrome) laminin-332 α3 chain
? α3 integrin
(rare variants in italics)
a Formerly known as generalized atrophic benign EB (GABEB)
b Formerly known as EB progressive
D: Classification scheme for all known dystrophic EB subtypes
Major DEB subtype Subtypes Affected protein
DDEB DDEB, generalized (DDEB-gen) type VII collagen
DDEB, acral (DDEB-ac)
DDEB, pretibial (DDEB-Pt)
DDEB, pruriginosa (DDEB-Pr)
DDEB, nails only (DDEB-no)
DDEB, bullous dermolysis of the newborn (DDEB-BDN)
RDEB RDEB, severe generalized (RDEB-sev gen)a type VII collagen
RDEB, generalized other (RDEB-O)
RDEB, inversa (RDEB-I)
RDEB, pretibial (RDEB-Pt)
RDEB pruriginosa (RDEB-Pr)
RDEB, centripetalis (RDEB-Ce)
RDEB, bullous dermolysis of the Newborn (RDEB-BDN)
(rare variants in italics)
a Previously called RDEB, Hallopeau-Siemens
Table 1. Classification system for inherited epidermolysis bullosa. Based on Fine et al. [4].
2. Dystrophic epidermolysis bullosa (DEB)
Mutations in the gene COL7A1, encoding for type VII collagen, cause the dystrophic form of
epidermolysis bullosa (DEB). Type VII collagen is the major constituent of the basement
membrane’s anchoring fibrils and belongs to the superfamily of collagens [5]. COL7A1 com‐
prises 118 exons and mostly short intervening introns resulting in a size of the entire
COL7A1 gene of 32kb encoding an mRNA of over 9kb [6,7]. The remarkable number of
COL7A1 mutations and the variable genotype-phenotype correlation hamper the finding of
an optimal therapy for DEB patients. Nevertheless severity of clinical manifestations can of‐
ten be defined by the type of the mutation and its localization within the COL7A1 gene [3].
DEB is divided into two main subtypes according to the mode of inheritance. Dominant
dystrophic EB (DDEB) is inherited in an autosomal dominant way, whereas recessive dys‐
trophic EB (RDEB) is transmitted in an autosomal recessive mode [8]. RDEB is classified in
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severe generalized RDEB (RDEB-sev gen) – formerly called RDEB, Hallopeau Siemens - and
RDEB-generalized other (RDEB-O) – formerly called RDEB-non Hallopeau Siemens [3].
The DDEB phenotype is mostly generalized but mild and clinically characterized by recurrent
blistering, milia, atrophic scarring, nail dystrophy and eventual loss of nails [3]. See Figure
1A,B. The fact that the defective and wildtype alleles are expressed equally explains the rela‐
tive mild phenotype in comparison to RDEB [3]. Missense mutations or in frame deletions in
COL7A1 causing RDEB disturb the assembly and aggregation of type VII collagen into anchor‐
ing fibrils. As a result, the number of anchoring fibrils and their morphology is altered signifi‐
cantly. The resulting subforms of RDEB are classified as RDEB, generalized other [3]. RDEB-
sev gen is caused by nonsense mutations in both alleles, resulting in a complete loss of type VII
collagen within the basal membrane zone of the skin. Clinical manifestations of RDEB are gen‐
eralized blistering, erosions, crusts, atrophic scarring, onychodystrophy, loss of nails, mutilat‐
ing pseudosyndactyly of hands and feet and functionally disabling contractures in hands, feet,
elbows and knees. See Figure 1C-H. Additionally, severe extracutaneous complications as gas‐
trointestinal and urogenital tracts involvement, external eye, chronic anaemia, growth retarda‐
tion and a high risk for the development of aggressive squamous cell carcinoma decrease
(Figure 1 I) the life quality of the patient [3,9-14].
Figure 1. Clinical phenotype of DEB. A,B: DDEB with milia formation and atrophy. C: Atrophic scar with crusts and
erosions in RDEB. D: Boy with severe-generalized RDEB leading to ulcerations and large non healing wounds with
atrophic scarring at the back; E: Nail dystrophy on both feet. F,G: Mitten formation in hands and feet. H: Severe caries
I: Squamous cell carcinoma on the foot (Photos: R. Hametner)
3. The dermal epidermal junction
The blisters characteristic for EB arise within the dermal-epidermal junction. Having a look
at this compartment of the skin helps to understand the cause of blistering in EB. The der‐
mal-epidermal junction is a complex basement membrane synthesized by dermal fibroblasts
and basal keratinocytes. Adhesion of the epidermis to the underlying dermis is mechanical‐
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ly supported by the so called basement membrane zone (BMZ). Moreover it regulates the
metabolic exchange between these two compartments. Up to now more than 20 macromole‐
cules situated in the dermal-epidermal-junction have been detected and characterized at bio‐
chemical and genomic level [2].
Three protein-junction complexes stabilize the adherence of the basal keratinocytes to the
dermis. See Figure 2. The hemidesmosomes built up by plectin, the bullous pemphigoid an‐
tigen 1 (BPAG1), α6β4 integrin and type XVII collagen (bullous pemphigoid antigen 2 -
BPAG2) link the basal keratinocytes with the basement membrane, spanning the lamina
lucida and anchored in the lamina densa [2]. Different laminin isoforms are located in the
lamina lucida (laminin-332, laminin 6, laminin 10) and contribute along with BPAG2 to the
formation of the anchoring filaments. The lamina densa is mainly built up by type VII colla‐
gen anchoring the lamina densa to the underlying dermis by the formation of anchoring fi‐
brils [2]. Some other antigens as uncein (19-DEJ-1 antigen), NU-T2 antigen, KF1 antigen,
LDA1 antigen, nidogen, heparin-sulfate, proteoglycan, antigens AF1 and AF2, thrombo‐
spondin, type V collagen and osteonectin/BM-40 have been detected in the lamina densa but
have not yet been adequately characterized [2].
Figure 2. Schematic setup of the cutaneous dermal-epidermal junction zone and localization of structural proteins
affected in inherited EB (Diagram by R. Hametner). laminin 5 = laminin 332; EBS = epidermolysis bullosa simplex; JEB =
junctional epidermolysis bullosa; DEB = dystrophic epidermolysis bullosa
4. Type VII collagen
Type VII collagen is classified in the superfamily of collagens [7]. A protein domain in triple-
helical conformation, which provides stability and integrity between connective tissues, is a
common structural feature of all collagens [7]. Type VII collagen is a minor collagen in human
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skin and demonstrates spatially restricted location but it plays a critical role in providing inte‐
gral stability to the skin because it is the major component of the anchoring fibrils [6,7].
5. Biology of type VII collagen
Type VII collagen molecules are characterized by the two non-collagenous NC-1 and NC-2
domains flanking a central collagenous, triple-helical segment [7]. In contrast to other inter‐
stitial collagens the repeating Gly-X-Y collagenous sequence is interrupted by 19 imperfec‐
tions due to insertions or deletions of amino acids. There is a 39 amino acid non-collagenous
hinge region susceptible to proteolytic digestion with pepsin in the middle of the triple-heli‐
cal domain [15]. The amino terminal NC-1 domain (approximately 145kD in size), is built up
of sub-modules with homology to known adhesive proteins, including segments with ho‐
mology to cartilage matrix protein (CMP), nine consecutive fibronectin type III-like (FN-III)
domains, a segment with homology to the A domain of von Willebrand factor, and a short
cysteine and proline-rich region [15]. The C-terminal non-collagenous NC-2 domain is with
30kD in size relatively small, and contains a segment with homology to Kuniz protease in‐
hibitor molecule [16,17].
The 32kb gene encoding a 9,2kb mRNA has been mapped to the short-arm of chromosome
3p21.1 [18]. The encoding primary sequence and the gene structure of type VII collagen are well
conserved. The mouse gene shows 90.4% identity at the protein level and 84.7% homology at
the nucleotide level, indicating the importance of type VII collagen as a structural protein [19].
The expression pattern of COL7A1 is tissue specific and restricted. Type VII collagen has
been detected by immunomapping to a selected number of epithelia, including the dermal-
epidermal BMZ of skin, the amniotic epithelial BMZ of the chorioamnion, the corneal epi‐
thelial basement membrane (Bowman’s membrane) and the epithelial basement membrane
of oral mucosa and cervix. Moreover the presence of type VII collagen correlates with the
presence of ultrastructurally detected anchoring fibrils [6]. A number of cytokines modulate
type VII collagen expression. Especially transforming growth factor-β is a powerful upregu‐
lator of COL7A1 at transcription level in fibroblasts and keratinocytes [20,21].
6. Type VII collagen – A major component of the anchoring fibrils
Type VII collagen is synthesized by two cell types in the skin: keratinocytes and fibroblasts [22].
After  synthesis  of  complete pro-α1 (VII)  polypeptides,  three polypeptides are associated
through their carboxy-terminal ends to a trimer molecule, which is then folded in its collage‐
nous segment into the triple-helical formation. Past to secretion into the extracellular milieu
two type VII collagen molecules are aligned into an anti-parallel dimer with the amino-termi‐
nal domains present at both ends of the molecule [6]. During dimer-assembly stabilization by
inter-molecular disulfide bond formation and a proteolytic removal of a part of the carboxy-
terminal ends (NC-2 domain) of both type VII collagen molecules take place [23]. Large num‐
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bers of these anti-parallel dimers aggregate laterally to form anchoring fibrils, which then can
be identified by their characteristic, centro-symmetric banding patterns in transmission elec‐
tron microscopy [7].
The affinity of the NC-1 domain to bind the principal components of the cutaneous base‐
ment membrane, laminin-332, laminin-311 and type IV collagen provides stability to the
dermo-epidermal adhesion on the dermal site at the lamina lucida/papillary dermis inter‐
face [6,24,25]. Arg-Gly-Asp sequences in the NC-1 domain serve as integrin mediated at‐
tachment sites for cells to adhere to extracellular matrix components such as fibronectin [26].
7. Mutations in COL7A1
Mutations in COL7A1 have clinical consequences in terms of disrupted integrity of the skin,
due to the complexity of the COL7A1 gene, type VII collagen protein structures and the criti‐
cal importance of its distinct domains in macromolecular interactions [7]. At least 324 patho‐
genic mutations have been detected within COL7A1 in different variants of DEB up to now
including 43 nonsense, 127 missense, 65 deletion, 28 insertion, 9 insertion-deletion, 51 splice-
site and 1 regulatory mutations [27]. See Figure 3-5. Exon 73 constitutes a region with a high
frequency of mutations, what suggests being a region in which mutations commonly affect
the function of anchoring fibrils [28]. RDEB is caused by nonsense, splice-site, deletions or
insertions, silent glycine substitutions within the triple helix and non-glycine missense mu‐
tations within the triple-helix or non-collagenous NC-2 domain [29]. RDEB-severe general‐
ized originates from nonsense, frameshift or splice-site mutations on both alleles leading to
premature termination codons (PTCs) [30], which result in nonsense mediated mRNA decay
or truncated proteins, leading to a reduced number of collagen VII monomers, which are
unable to assemble into functional anchoring fibrils [29,30]. PTC mutations do not cause a
clinical phenotype if they appear in the heterozygous state, but if they are homozygous or
combined with another PTC mutation they are causing severe generalized RDEB [27]. Two
missense mutations or compound heterozygosity of a missense and a PTC mutation lead to
severe generalized RDEB in very rare cases [31].
RDEB, generalized other, the milder phenotype, is mostly caused by PTCs, small deletions,
substitutions of glycine residues in the collagenous domain, splice-site mutations within
NC-2 [32-35], delayed termination codons [36], in frame exon skipping [29,36], or missense
substitution mutations involving amino acids other than glycine [29,37,38], the majority in‐
volving arginine residues resulting either in the loss of an ionic charge or in the introduction
of a bulky chain at an external position of the triple helix [27]. Thereby these mutations usu‐
ally concern a critical amino acid and change the conformation of the protein, which then
might still be able to assemble into a small number of anchoring fibrils but is likely to be
unstable when they laterally aggregate. Anyhow some full length type VII collagen poly‐
peptides can still be built up [39].
DDEB is caused by glycine substitutions within the triple helical domain of COL7A1 or other
missense mutations, deletions or splice site mutations in some cases [5,26,40-44]. Critical ami‐
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no acids in the structure of the triple helix are affected by these mutations and therefore the
overall stability of the anchoring fibrils is disturbed. More than 100 missense mutations result‐
ing in a Gly-Xaa substitution have been detected in the collagenous domain of COL7A1; half of
these are situated in amino acids 1522-2791 and have a dominant negative effect [27].
Figure 3. Missense and nonsense mutations in DEB patients. The red lettering signifies dominant and the black
signifies recessive inheritance. (Dang et al. [27] © 2008 Blackwell Munksgaard, Experimental Dermatology)
Figure 4. COL7A1 deletions, insertions and splice site mutations in DEB patients. The red lettering signifies dominant
and the black signifies recessive inheritance. (Dang et al. [27] © 2008 Blackwell Munksgaard, Experimental Dermatology)
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Figure 5. Glycine substitutions in DEB. These are all in the triple-helical collagenous domain; the ones above repre‐
sent DDEB, the ones below RDEB. (Dang et al. [27] © 2008 Blackwell Munksgaard, Experimental Dermatology)
8. Mouse model
So far there are only two viable mouse models with defects in the COL7A1 gene. A transgen‐
ic mouse carrying human COL7A1 cDNA inclusive the human 7528delG mutation in exon
101, which develops the DEB phenotype gradually [45], and a collagen VII hypomorphic
mouse published by Fritsch et al. 2008 [46]. In the collagen VII hypomorphic mouse reduced
expression of collagen VII originates from aberrant splicing resulting from the introduction
of a phosphoglycerate kinase promoter-driven neomycin phosphotransferase expression
cassette (PGK-Neo cassette) in intron 2 of COL7A1. One out of three possible splice variants
is translated into full-length type VII collagen resulting in a reduction of type VII collagen
levels to about 9% of wildtype levels in COL7A1flNeo/flNeo mice. Hemorrhagic blisters on the
soles of fore and hind paws, ears and mouth are developed by the collagen VII mice within
the first 48 hours of life. Blisters of newborn COL7A1flNeo/flNeo mice were histopathologically
classified as hemorrhagic and subepidermal. Type VII collagen immunofluorescence stain‐
ing revealed weak reactivity in comparison to wildtype littermates. Ultrastructurally normal
but reduced in number anchoring fibrils were detected in transmission electron microscopy
of the dermal-epidermal junction of the skin. COL7A1flNeo/flNeo mice suffer from growth retar‐
dation due to malnutrition and subsequently have a reduced life expectancy. Moreover
healing of the initial blistering on the paws with scarring results in the development of mit‐
ten deformities beginning at 2-3 weeks of age [46].
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9. Therapy approaches
Due to the size of the COL7A1 gene, a causal therapy for dystrophic epidermolysis bullosa is
a great challenge. Symptomatic therapy is concentrated on prevention of skin trauma to
minimize blister formation, prevention of secondary bacterial infection, treatment of infec‐
tion, measures to improve wound healing, maintenance of good nutrition, treatment of cor‐
rectable complications, and finally rehabilitation [3]. However, several gene and cell therapy
strategies showed the potential to revert the disease-associated phenotype. Phenotypic cor‐
rection of recessive DEB forms (RDEB) can be achieved by gene insertion therapy, in which
the wildtype sequence of a mutated gene of interest is introduced into the target cells. More‐
over alternative avenues including gene-, cell-, protein- and other systemic- therapy ap‐
proaches have been tested to restore type VII collagen expression. See Table 2.
Author Approach Year
Woodley et al. Type VII collagen minigene 2000
Sat et al. Cosmid clone containing the entire COL7A1 gene 2000
Mecklenbeck et al. Microinjection of a COL7A1-PAC vector 2002
Urda et al. ФC31 bacteriophage integrase 2002
Chen et al. Minimal lentiviral vectors 2002
Baldeschi et al Canine type VII collagen 2003
Woodley et al Targeting fibroblasts instead of keratinocytes (lentivirally) 2003
Gache et al. Full-length cDNA (retrovirally) 2004
Woodley et al. Intradermal injection of recombinant type VII collagen 2004
Woodley et al. Intradermal injection of lentiviral vectors in vivo 2006
Goto et al. Targeting fibroblasts instead of keratinocytes (retrovirally) 2006
Goto et al. Targeted exon skipping using antisense 2006
Wong et al. Intradermal injection of allogenic wildtype fibroblasts into a patient 2007
Fritsch et al. Intradermal injection of murine wildtype fibroblasts in a DEB mouse model 2008
Remington et al. Intradermal injection of human type VII collagen in mice 2009
Titeux et al. Minimal self-inactivating retroviral vectors harbouring the full length human
COL7A1 gene
2010
Wagner et al. Allogeneic bone marrow transplantation 2010
Siprashvili et al. Full-length cDNA (retrovirally) 2010
Murauer et al. 3´ Trans-splicing of COL7A1 2011
Table 2. Therapy approaches to restore type VII collagen expression
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Woodley et al.  used a type VII collagen minigene, which contains the intact noncollage‐
nous domains NC1 and NC2 and part of the central collagenous domain. This approach
resulted after transduction into DEB keratinocytes in persistent synthesis and secretion of
a  230kDa  recombinant  minicollagen  VII  [47].  However  deletions  in  COL7A1  have  been
reported to  be  associated with  a  pathologic  phenotype [5,48,49].  The same group intro‐
duced  recombinant  human  type  VII  collagen  into  mouse  and  human  skin  equivalents
transplanted onto mice,  by injection.  As a  result  the  injected type VII  collagen was de‐
tected within the basal  membrane zone leading to  a  reversion of  the disease associated
phenotype [50].  Additionally,  the  group expressed type  VII  collagen using a  self-inacti‐
vating lentiviral vector, which was injected into human skin equivalents, expanded from
DEB  cells,  placed  on  nude  immunodeficient  mice.  Experiments  revealed  the  synthesis
and insertion  of  the  protein  into  the  basal  membrane  zone  [51].  Using  a  cosmid clone,
carrying the  entire  COL7A1  gene,  was  also  shown to  be  a  promising way to  direct  ex‐
pression of  type VII  collagen in skin in fetal  and neonatal  mice.  The tested neonatal  or
fetal mice produced type VII collagen within the basal membrane zone of the skin show‐
ing a stable expression of the protein in vivo [52]. Microinjection of a P1-derived artificial
chromosome (PAC) carrying the entire COL7A1  locus resulted in production of a procol‐
lagen  VII  similar  to  the  authentic  one  by  Mecklenbeck  et  al.  [53].  The  ΦC31  bacterio‐
phage integrase,  facilitating integration only in  pseudo attP sites,  was used to  integrate
COL7A1  stably  into  DEB primary epidermal  progenitor  cells  by Urda et  al.  [54].  Balde‐
schi et al.  also showed sustained and permanent expression of the transgene after trans‐
duction of canine type VII collagen into human and canine DEB keratinocytes [55]. Based
on this study Gache et al. yield a full phenotypic reversion of the disease-associated phe‐
notype of RDEB epidermal clonogenic cells after full-length human COL7A1 cDNA intro‐
duction  using  a  retroviral  system.  However,  the  expression  of  COL7A1  was  50  times
higher than the levels monitored in wildtype keratinocytes in monolayers, increasing the
risk  for  an ectopic  transgene expression and an abnormal  accumulation in  skin  equiva‐
lents [56]. Chen et al. used a minimal lentiviral vector for COL7A1  expression in vitro  as
an alternative  to  the  retroviral  system applied by Gache et  al.  [57].  Goto  et  al.  showed
that COL7A1  treated fibroblasts of skin grafts provide higher amounts of type VII colla‐
gen  for  the  dermal-epidermal  junction  than  keratinocytes  [58].  They  have  also  demon‐
strated  an  antisense  oligoribonucleotide  therapy  to  maintain  exon  skipping  of  an  exon
comprising  a  premature  stop  codon.  As  a  result  a  truncated  type  VII  collagen  variant
was  expressed  [59].  Additionally,  intradermal  injection  of  untreated  normal  human  or
gene-corrected  fibroblasts  in  mice  can  result  in  a  stable  production  of  human type  VII
collagen at the basal membrane zone of the skin [60]. Moreover, Wong et al. demonstrat‐
ed an increased source of type VII collagen in the dermal-epidermal junction for at least
three months after intradermal injection of allogeneic fibroblasts [61].  In a mouse model
Fritsch et al. showed an accumulation of type VII collagen and restoration of a function‐
al  dermal-epidermal  junction  after  injection  of  murine  wildtype  fibroblasts  into  a  type
VII collagen hypomorphic mouse [46]. In 2009 Remington et al. injected human type VII
collagen  into  COL7A1  -/-  mice,  also  restoring  type  VII  collagen  expression  and  correct
generation  of  anchoring  fibrils  [62].  Titeux  et  al.  transduced  COL7A1  cDNA  under  the
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control  of  a  human  promoter  using  a  minimal  self-inactivating  retroviral  vector  into
RDEB keratinocytes and fibroblasts leading to cell correction and long lasting expression
of  type  VII  collagen.  The  dermal-epidermal  junction  in  generated  skin  equivalents  was
restored [63]. A similar strategy was shown by Siprashvili et al. using an epitope-tagged
COL7A1  cDNA, providing a long term expression of the protein in skin equivalents [64].
In a clinical trial executing a bone marrow transplantation 6 RDEB patients received allo‐
geneic stem cells  to milder the RDEB phenotype.  As a result,  5  patients showed an im‐
proved wound healing, but one patient died [65].
Until now, no ex vivo gene therapy approach passed through a phase I/II gene therapy trial.
Most of these applications are focusing on the transfer of full-length COL7A1 cDNA into the
affected patient cells. The drawbacks of the insertion of the full-length 9kb cDNA of COL7A1
are the cloning and packaging limitations of commonly used vector systems to transduce
keratinocytes or fibroblasts and the instability of the COL7A1 gene due to possible genetic
rearrangements of the large repetitive cDNA sequence [47]. Additionally, the influence of
COL7A1 over- or ectopic expression in treated cells has to be clarified for a clinical applica‐
tion. Using the methodology of spliceosome mediated RNA Trans-splicing (SMaRT) can be a
promising alternative to the mentioned approaches to cope with some of the suspected is‐
sues present in full-length COL7A1 replacement strategies. Murauer et al. demonstrated the
exchange of the 3´ coding COL7A1 cDNA region spanning from exon 65 to the last exon 118
by SMaRT [66]. Thereby the risk of genetic rearrangements of the COL7A1 cDNA sequence
should be reduced significantly. Alternatively to this, we will present in this work a 5´ exon
replacement strategy using SMaRT, providing the possibility to repair also relevant muta‐
tions 5´ within the COL7A1 gene.
10. Spliceosome mediated mRNA Trans-splicing
10.1. General aspects
RNA trans-splicing is a naturally occurring event to recombine two or more mRNA mole‐
cules to a new chimeric gene product [67]. For therapeutic purposes such products can be
generated by trans-splicing a second RNA species from a RNA trans-splicing molecule
(RTM) into the 3´, 5´ or internal sequence of an endogenously expressed target. See Figure 6.
The main advantages of this methodology are the possibility to reduce the size of the trans‐
gene, the maintained endogenous regulation of transgene expression and the feasibility to
treat dominant negative diseases [68]. Undesired gene expression due to unintended deliv‐
ery or misregulation is minimized as trans-splicing should only occur in cells expressing the
target pre-mRNA [69]. Furthermore, SMaRT offers the potential for correction of dominant
negative mutations into wildtype gene products [70].
10.2. Methodology of spliceosome mediated mRNA trans-splicing (SMaRT)
In  SMaRT  constructs  that  are  engineered  to  bind  the  introns  of  specific  pre-mRNAs  –
RNA trans-splicing  molecules  (RTMs)  -  are  the  key  players.  These  RTMs effect  a  trans-
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splicing  event  between  the  target  pre-mRNA  and  the  RTM  which  is  mediated  by  the
spliceosome. An RTM carries three domains; i)  a binding domain complementary to the
target intron to localize the RTM to the target pre-mRNA; ii) a splicing domain contain‐
ing splicing elements for efficient trans-splicing; and iii) a coding domain comprising one
or more wildtype exons that are trans-spliced to the target. The cis-splicing elements and
the binding domain are  not  retained in  the  modified RNA product  [71].  Depending on
the gene portion to  replace,  SMaRT can be divided into 3´,  5´  or  internal  exon replace‐
ment [69]. See Figure 6.
Figure 6. Schematic overview on different applications of SMaRT. A:3`Trans-splicing: If there is a mutation in the 3´
part of the target gene a wildtype mRNA can be obtained by 3´splicing. Therefore, a 3´RTM with a binding domain
situated in the intron 5´ to the first exon to be exchanged is necessary. E.g. if the mutation to be corrected is in exon
15, a binding domain for intron 14 is designed. This RTM can correct mutations more 3´ as well. After binding of the
RTM the two mRNAs are trans-spliced and combined into a wildtype mRNA. B: 5`Trans-splicing: If correction of a
mutation in the 5´ part of a gene is desired a 5´ RTM with a binding domain located in the intron 3´ to the exon to be
exchanged is created. If the mutation to be corrected with 5´splicing is in exon 15, a RTM with a binding domain in
intron 15 is required. This RTM can repair mutations more 5´ than exon 15 as well. C: Internal Trans-splicing: There is
also a method to exchange only one exon, called internal trans-splicing or internal exon replacement (IER). Here an
RTM with two binding domains and 5´ and 3´ splice elements is applied. Arrowheads indicate mutations.
10.3. Efficiency of SMaRT
The efficiency of trans-splicing to correct genetic defects and acquired disorders at pre-
mRNA level has already been demonstrated for 3´ as well as for 5´ trans-splicing in different
diseases in vitro and in vivo. See Table 3.
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Author Approach Year
3´ trans-splicing
Puttaraju et al. 3´ repair of lacZ in a tractable system 2001
Chao et al. 3´ repair of haemophilia A mice in vivo 2003
Dallinger et al. 3´ repair in a lacZ model system in a keratinocyte specific background 2003
Liu et al. 3´ repair of CFTR mRNA (adenovirally) 2005
Rodriguez-Martin et al. 3´ reprogramming of tau alternative splicing in a model system 2005
Zayed et al. 3´ repair of DNA-PKcs in SCID (delivery via sleeping beauty) 2007
Chen et al. 3´ repair dystrophia myotonica type 1 pre-mRNA 2008
Coady et al. 3´ SMN2 trans-splicing in combination with blocking an cis-splice sit in mice
in vivo
2010
Murauer et al. Functional 3´ repair of the COL7A1 gene 2010
Wang et al. 3´ introduction of therapeutic proteins in highly abundant albumin
transcripts in mice in vivo
2009
Gruber et al. 3´ reprogramming of tumor marker genes to introduce suicide genes 2011
5´trans-splicing
Mansfield et al. 5´ repair of CFTR mRNA 2000
Kierlin-Duncan et al. 5´ repair of β-globin mRNA 2007
Wally et al. 5´ repair of the PLEC1 gene 2007
Wally et al. 5´ K14 mRNA reprogramming 2010
Rindt et al. 5´ trans-splicing repair of huntingtin at mRNA level 2012
Internal trans-splicing
Lorain et al. Exon exchange approach to repair Duchenne dystrophin transcripts in a
minigene
2010
Koller et al. A screening system for IER molecules 2011
Table 3. Overview on functional trans-splicing approaches so far.
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RNA trans-splicing for gene correction is usually performed by 3’ RNA trans-splicing to ex‐
change 3’ coding parts of a gene of interest. 3´ RNA trans-splicing was successfully applied
to restore wildtype gene expression pattern amongst others in patient cells or in animal
models of epidermolysis bullosa, cystic fibrosis, X-linked immunodeficiency and hemophilia
A [66,72,73]. Primarily co-transfection experiments with RTMs and artificial targets were
used to give proof of principle of functionality of the trans-splicing process.
So  a  tractable  lacZ  model  repair  system,  in  which  user  defined  target  introns  can  be
trans-spliced into a mutated lacZ gene to test target specific 3´ RTMs by double transfec‐
tion in 293T cells  was developed by Puttaraju et  al..  Functional  lacZ correction was de‐
tected  on  mRNA  and  protein  level  by  qRT-PCR  and  western  blotting  for  one  CFTR
intron  [74].  Chao  et  al.  showed that  the  hemophilia  A phenotype  in  factor  VIII  (FVIII)
knockout  mice  can  be  repaired  by  the  introduction  of  a  3’  RTM.  After  delivery  of  the
DNA through the portal vein, the FVIII protein was detected by western blot analysis of
cryoprecipitated  murine  plasma.  Long-term  correction  was  shown  via  adenoviral  tail
vein  transduction  of  the  specific  RTM.  In  the  classical  tail-clip  test  all  naive  knockout
mice died, whereas eight out of ten treated mice survived, indicating that 3´  trans-splic‐
ing is suitable to correct the bleeding disorder in hemophilia A [73]. Liu et al. used a re‐
combinant  adeno-associated viral  vector  system to target  the human cystic  fibrosis  (CF)
polarized  airway  epithelia  from  the  apical  membrane.  The  measurement  of  the  cAMP-
sensitive short circuit currents levels confirmed the CFTR correction by SMaRT [75]. Dal‐
linger et al. showed as a proof of principle in the skin the correction of the EB-associated
gene COL17A1  by 3’ trans-splicing. Using a lacZ model repair system, an intron specific
target molecule and a rationally designed RTM, the feasibility of SMaRT was shown by
co-transfection experiments  in  keratinocytes  [76].  Using a  minigene Rodriguez-Martin et
al.  published functional 3´ trans-splicing on mRNA level after double transfection of the
minigene and specific 3´RTM in COS-7 and SH-SY5Y cells for tau mRNA [77].  Zayed et
al.  demonstrated 3´  correction of  the  DNA protein kinase  catalytic  subunit  (DNA-PKcs)
gene,  which  is  responsible  for  severe  combined  immune  deficiency  (SCID).  Specific  3
´RTMs were transfected into scid.adh cells using the Sleeping Beauty transposon system.
After  this  treatment  irradiated cells  showed an 4.3  fold  increase  of  surviving cells  over
irradiated untreated scid.adh cells.  Correction of the mutation was shown via QRT-PCR
and sequencing on mRNA level. Additionally, functional 3´trans-splicing was detected on
mRNA level via sequencing and on protein level  via western blotting in SCID multipo‐
tent adult progenitor cells [78]. Chen et al. corrected the dystrophia myotica protein kin‐
ase  gene  responsible  for  the  most  common  muscular  dystrophy  in  adults  by  3´  trans-
splicing on mRNA level  [79].  Coady et  al.  showed in vivo  correction of spinal muscular
atrophy  (SMA)  by  3´trans-splicing  in  mice  recently.  A  single  injection  of  a  repair  con‐
struct  trans-splicing  SMN2  carried  by  a  PMU3  vector  into  the  intracerebral-ventricular
space  of  SMA  neonates  lessens  the  severity  of  the  SMA  phenotype  in  a  severe  mouse
model  and extends survival  by around 70% [80].  Murauer  et  al.  corrected mutations  in
COL7A1  by  3´trans-splicing.  RDEB  keratinocytes  retrovirally  transduced  with  a  3´trans-
splicing molecule showed an increase of COL7A1 mRNA sqRT-PCR and recovery of full-
length  type  VII  collagen  expression  on  protein  level  in  western  blot  and
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immunofluorescent staining. Moreover normal morphology and reduced invasive capaci‐
ty was achieved in transduced cells. Correct localization of type VII collagen at the base‐
ment  membrane  zone  in  skin  equivalents,  where  it  assembles  into  anchoring  fibril  like
structures,  showed the potential  of  trans-splicing to correct  an RDEB phenotype in  vitro
[66]. There are also alternative approaches in which therapeutic proteins are produced af‐
ter  specific  3´trans-splicing  events  into  highly  abundant  albumin  transcripts  using  3
´RTMs [81].  Another  area  of  application  of  SMaRT was  performed by  Gruber  et  al.  to
treat  malignant  SCC  tumors,  which  are  life-threatening  issues  for  RDEB  patients.  The
transfection of  RDEB SCC cells  with a designed 3’  RTM lead to the fusion of  the toxin
streptolysin O, carried by a 3’ RTM, to MMP-9 pre-mRNA molecules, resulting in the ex‐
pression of the toxin and subsequently to the cell death of transfected tumor cells [82].
5’  trans-splicing to correct  upstream coding sequences of  an mRNA of interest  was first
shown  by  a  double  transfection  model  to  repair  mutations  in  the  cystic  fibrosis  trans‐
membrane receptor (CFTR) pre-mRNA. Functionality tests  were performed by anion ef‐
flux  transport  measurements.  RTMs  were  designed  capable  to  repair  the  5’  portion  of
CFTR transcripts [83]. 5’ trans-splicing was also applied for the substitution of exon 1 of
b-globin in cells co-transfected with a target molecule and an RTM in 293T cells and lead
specific trans-splicing detected by one step RT-PCR [84]. Endogenous 5’ trans-splicing in‐
duced gene correction was first  demonstrated by Wally  et  al.  on the basis  of  the PLEC
gene  involved  in  the  disease  epidermolysis  bullosa  simplex  (EBS).  Restoration  of  wild‐
type  plectin  expression  patterns  was  shown  by  immunofluorescence  microscopy  of  pa‐
tient fibroblasts after RTM treatment [61]. Additionally, exons 1–7 of the keratin 14 gene
(KRT14) were replaced in an autosomal dominant model of EBS resulting in recovery of
K14 on RNA and protein  level,  detected by SQRT-PCR,  western  blotting  and immuno‐
fluorescence staining by transient transfection of specific  5´  RTMs chosen in a screening
procedure [85].  Recently 5´trans-splicing correction of a disease causing huntingtin allele
on mRNA level was reported by Rindt et al. [86].
Lorain et al. primarily published the methodology of internal exon replacement (IER) to cor‐
rect a dystrophin minigene on mRNA level [87]. Recently, Koller et al. developed a new
RTM screening system to improve double RNA trans-splicing for the correction of the EB as‐
sociated gene COL17A1 [88].
10.4. RTM screening systems
So far,  there are  no general  rules  for  the design of  highly efficient  trans-splicing RTMs.
However,  recent  studies revealed the influence of  minor differences in length,  composi‐
tion  and  localization  of  the  binding  domain  (BD)  on  RTM  efficiency  and  specificity
[85,88]. Due to the fact that an RTM can’t be predicted rationally, we established a fluo‐
rescence-based screening system to select an efficient RTM from a pool of randomly de‐
signed RTMs. This screening system is composed of fluorescence-based RTM backbones,
in which randomly created binding domains are cloned, and a gene specific target mole‐
cule. The target binding region (exon/intron sequence of a gene of interest) is PCR ampli‐
fied,  randomly fragmented and cloned into the RTM vector.  The coding region consists
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of a fluorescence reporter,  divided into two (5’ or 3’  trans-splicing) or three parts (inter‐
nal  exon replacement)  and distributed to both screening molecules (target molecule and
RTM). The RTM library is composed of individual RTMs with various binding domains.
Their  efficiency  can  be  evaluated  by  fluorescence  microscopy  and  flow  cytometry.  For
flow cytometric analysis, individual selected RTMs of the RTM library are co-transfected
with  the  designed  target  molecule,  including  the  full-length  target  binding  region,  and
the missing sequence of the split fluorescence reporter into HEK293FT cells. Co-transfec‐
tion of RTM and target molecule into HEK293FT cells results in the restoration of expres‐
sion of the fluorescence reporter.  The intensity of the fluorescence signal of the reporter
molecule  gives  information  on  the  functionality  of  the  binding  domain.  The  most  effi‐
cient BDs can be tested for endogenous experiments in patient cells. After transfection of
the screening-RTM, the fusion of the splitted trans-splicing reporter and the endogenous
target is detected by RT-PCR. To develop an mRNA based gene therapy an RTM, carry‐
ing the wildtype sequence instead of  the coding sequence of  the fluorescence molecule,
is constructed. After RTM treatment of patient cells a mutated gene part is exchanged by
trans-splicing and wildtype transcripts are restored.
11. RTMs for the murine COL7A1 gene
We started to establish 5´ trans-splicing for murine COL7A1 in order to analyze the function‐
ality of RNA trans-splicing in vivo, due to the existence of a mouse model carrying a neo cas‐
sette in intron 2 of COL7A1 generating aberrant splice variants, which lead to a reduction of
type VII collagen expression [46]. By close similarity of this mouse model to the human
RDEB phenotype and location of the defect in the 5´ part of COL7A1, this mouse model ex‐
hibits obviously an ideal system to test our 5´ repair molecules and investigate different ap‐
plication strategies.
Intron 15 was chosen as target intron because its size of about 1,5kb allows to create a large
number of different binding domains. To generate a large amount of different RTMs, con‐
taining binding domains with different binding affinities to the target intron, the target
exon/intron was digested out of the artificial target used in the screen with HindIII and
BamHI and digested with CviJI*. The resulting fragments with a length of 50-750bp were
cloned into the RTM backbone. Binding domains were identified by colony PCR using a for‐
ward primer situated in the 5´ half of the split GFP and a vector specific reverse primer. Pos‐
sible binding domains with different lengths were detected on a 2% agarose gel after gel
electrophoresis. To check orientation and location of the binding domain, clones with inserts
were sequenced. To evaluate the created RTM library the artificial target containing the tar‐
get intron (intron15) and the 3´ half of the split AcGFP instead of the 3´ part of murine
COL7A1 was cotransfected with the RTM library respectively individual RTMs into
HEK293FT. The RTMs contain a transfection reporter (DsRED), the 5´ half of the split
AcGFP instead of the first 15 exons of COL7A1 and variable binding domains. The cotrans‐
fected cells were analyzed concerning their AcGFP/DsRED expression ratios by fluorescence
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microscopy and flow cytometry, whereby a higher ratio indicates the presence of a more
functional binding domain in the RTM. See Figures 7+8.
Figure 7. Fluorescence microscopy of with RTM library and target double transfected HEK293 cells. A: Functional
binding domains lead to specific trans-splicing of the two pre mRNAs which are then combined into one mRNA con‐
taining DsRED and full-length AcGFP. Red fluorescence indicates the transfection of a RTM in the cells whereas red
and green fluorescence indicates functional trans-splicing. B: Double transfection of an artificial target containing
exon/intron 15 of murine COL7A1 and an RTM library for this exon/intron in HEK293FT. C: Double transfection of an
artificial target containing exon/intron 15 of murine COL7A1 and the best RTM for this intron.
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Figure 8. Flow cytometric analysis: 5´ screen for murine COL7A1 exon/intron 15. Red fluorescence (shown on Y-axis)
indicates transfection of RTMs in the cells; green fluorescence (shown on X-axis) indicates specific trans-splicing. A:
The positive control is a vector containing a DsRED linker AcGFP construct. This FACS plot mimics the AcGFP and
DsRED ratios expected from the product of optimal trans-splicing. B: The RTM library shows a trans-splicing efficiency
(AcGFP/DsRED ratio) of 48,94% calculated from trans-splicing positive cells/all transfected cells.(B2 1,8% + B4 0,5%)/
(B1 2,4% + B2 1,8% + B4 0,5%) The fact, that several cells seem to be exclusively green can be explained by the in‐
tense AcGFP fluorescence, which tends to override the weaker DsRED fluorescence. C: The most efficient RTM ana‐
lyzed, with a trans-splicing efficiency of 96,55%, (B2 4,6% + B4 3,8%)/( B1 0,3% + B2 4,6% + B4 3,8%) shows a dot
plot pattern similar to the positive control. Therefore the binding domain of RTM +3A was chosen to be used in fur‐
ther endogenous experiments. D: A Comparison of AcGFP/DsRED ratios of single RTMs containing different binding
domains, shows a wide variability of AcGFP/DsRED ration spanning less than 10% to nearly 100%.
The RTM with the highest AcGFP/DsRED ratio (RTM+3A) was chosen for further endoge‐
nous experiments. To check endogenous functionality of the RTM was transiently transfect‐
ed into an immortalized murine keratinocyte cell line [46]. The 5´ part of the split AcGFP
contained by the screening RTM was specifically trans-spliced with its endogenous target –
the murine COL7A1 mRNA – resulting in a AcGFP-COL7A1 fusion mRNA detected by RT-
PCR analysis and subsequent sequencing. See Figure 9.
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Figure 9. Endogenous trans-splicing into exon/intron 15 of murine COL7A1. A: RT-PCR analysis of transiently RTM+3A
transfected spontaneously immortalized mouse wildtype keratinocytes [46] using primers in the 5´ part of split AcGFP
and in exon 18 of COL7A1 resulted in detection of a 365bp band after agarose gel-electrophoresis. B: The fragment
was verified to be an AcGFP-COL7A1 fusion by sequencing. +3A cDNA analysis of spontaneously immortalized mouse
wildtype keratinocytes transiently transfected with RTM +3A L Ladder Mix DNA marker
12. Conclusion
RNA trans-splicing is a useful methodology to reprogram genes for diagnostic and thera‐
peutic purposes. Due to a variety of advantages over traditional gene-replacement strat‐
egies, RNA trans-splicing is used to correct the phenotype of many genetic diseases in vitro,
ranging from epidermolysis bullosa to neurodegenerative diseases. In vivo studies are in
progress to accelerate the way to the medical use of this RNA-based application.
We have established all three modes of trans-splicing (5’, 3’ and internal exon replacement)
in our laboratory on the basis of several EB-associated genes (KRT14, PLEC, COL7A1,
COL17A1). In this work we focused on the methodology of 5´ RNA trans-splicing to correct
mutations localized within the first 15 exons of the murine COL7A1 gene encoding for type
VII collagen. COL7A1 is a large gene with over 9kb and is therefore suitable for this ap‐
proach, in which only a short RTM has to be designed, harbouring only the first 15 exons of
the gene. Using an RTM screening system, described by Wally et al 2011 [89], it should be
possible to increase the trans-splicing efficiency of designed RTMs to a level where the phe‐
notype of COL7A1 deficient cells can be converted into wildtype. We analyzed the binding
properties of randomly designed RTMs specific for intron 15 of murine COL7A1 and tested
the most efficient RTM in COL7A1 deficient keratinocytes for endogenous functionality. The
RTM was able to induce endogenous 5´trans-splicing into murine COL7A1 pre-mRNA mole‐
cules, manifested in the fusion of the 5’ GFP part of the RTM with exon 16 of COL7A1. Next
steps are the exchange of the 5’ GFP part by the 5´sequence of murine COL7A1 (exons1-15)
and to investigate if our RTMs are able to increase the level of full-length COL7A1 mRNA
leading to the recovery of functional type VII collagen in COL7A1 deficient cells and in skin
equivalents. In summary we demonstrated a novel RNA-based strategy to correct disease-
associated mutations within COL7A1, thereby avoiding or minimizing many problems
present in standard cDNA gene therapies including fragmentation of the large COL7A1
gene, the size limitation of the transgene and over- and ectopic expression of the transgene.
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The development of a gene therapy for type VII collagen deficiency would increase the
chance to find a cure for dystrophic EB. Additionally, the improvement of the methodology
of 5’ RNA trans-splicing will help us to move closer to the treatment of other genetic diseas‐
es caused by mutations in especially large genes.
Acknowledgements
We want to thank Prof. Leena Bruckner-Tuderman for providing the murine keratinocytes.
Moreover we thank the Austrian Science Fund (FWF) for financing the project “Develop‐
ment of a 5´trans-splicing Gene Therapy” [P22039-B12] and DEBRA Austria, DEBRA Alto
Adige and the Paracelsus Private Medical University for additional financial support.
Author details
E. Mayr*, U. Koller and J.W. Bauer
*Address all correspondence to: el.mayr@salk.at
EB House Austria, Dept Dermatol, Paracelsus Med Univ, Salzburg, Austria
References
[1] Laimer M, Lanschuetzer CM, B, Pohla-Gubo G, Klausegger A, Diem A, Riedl R, Ba‐
uer JW, and Hintner H. Epidermolysis Bullosa. Pädiatrie&Pädologie 2006;6 30-38.
[2] Kanitakis J. Anatomy, Histology and Immunohistochemistry of Normal Human
Skin. European Journal of Dermatology 2002;12(4) 390-400.
[3] Fine JD and Hintner H. Life With Epidermolysis Bullosa .Wien: Springer Wien;
[4] Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner
H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA, Mellerio JE, Murrell DF, Shimi‐
zu H, Uitto J, Vahlquist A, Woodley D, and Zambruno G. The Classification of Inher‐
ited Epidermolysis Bullosa (EB): Report of the Third International Consensus
Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008;58(6)
931-950.
[5] Pulkkinen L and Uitto J. Mutation Analysis and Molecular Genetics of Epidermolysis
Bullosa. Matrix Biol 1999;18(1) 29-42.
[6] Sakai LY, Keene DR, Morris NP, and Burgeson RE. Type VII Collagen Is a Major
Structural Component of Anchoring Fibrils. J Cell Biol 1986;103(4) 1577-1586.
Gene Therapy for the COL7A1 Gene
http://dx.doi.org/10.5772/51926
581
[7] Chung HJ and Uitto J. Type VII Collagen: the Anchoring Fibril Protein at Fault in
Dystrophic Epidermolysis Bullosa. Dermatol Clin 2010;28(1) 93-105.
[8] Fine JD, Eady RA, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A,
Heagerty A, Hintner H, Jonkman MF, McGrath J, McGuire J, Moshell A, Shimizu H,
Tadini G, and Uitto J. Revised Classification System for Inherited Epidermolysis Bul‐
losa: Report of the Second International Consensus Meeting on Diagnosis and Classi‐
fication of Epidermolysis Bullosa. J Am Acad Dermatol 2000;42(6) 1051-1066.
[9] Fine JD, Johnson LB, Weiner M, and Suchindran C. Gastrointestinal Complications of
Inherited Epidermolysis Bullosa: Cumulative Experience of the National Epidermol‐
ysis Bullosa Registry. J Pediatr Gastroenterol Nutr 2008;46(2) 147-158.
[10] Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, Devries DT, and Suchin‐
dran C. Eye Involvement in Inherited Epidermolysis Bullosa: Experience of the Na‐
tional Epidermolysis Bullosa Registry. Am J Ophthalmol 2004;138(2) 254-262.
[11] Fine JD, Johnson LB, Weiner M, and Suchindran C. Tracheolaryngeal Complications
of Inherited Epidermolysis Bullosa: Cumulative Experience of the National Epider‐
molysis Bullosa Registry. Laryngoscope 2007;117(9) 1652-1660.
[12] Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, Devries DT, and Suchin‐
dran C. Pseudosyndactyly and Musculoskeletal Contractures in Inherited Epider‐
molysis Bullosa: Experience of the National Epidermolysis Bullosa Registry,
1986-2002. J Hand Surg Br 2005;30(1) 14-22.
[13] Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, Devries DT, and Suchin‐
dran C. Genitourinary Complications of Inherited Epidermolysis Bullosa: Experience
of the National Epidermylosis Bullosa Registry and Review of the Literature. J Urol
2004;172(5 Pt 1) 2040-2044.
[14] Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, Devries DT, and Suchin‐
dran C. Inherited Epidermolysis Bullosa and the Risk of Death From Renal Disease:
Experience of the National Epidermolysis Bullosa Registry. Am J Kidney Dis
2004;44(4) 651-660.
[15] Christiano AM, Rosenbaum LM, Chung-Honet LC, Parente MG, Woodley DT, Pan
TC, Zhang RZ, Chu ML, Burgeson RE, and Uitto J. The Large Non-Collagenous Do‐
main (NC-1) of Type VII Collagen Is Amino-Terminal and Chimeric. Homology to
Cartilage Matrix Protein, the Type III Domains of Fibronectin and the A Domains of
Von Willebrand Factor. Hum Mol Genet 1992;1(7) 475-481.
[16] Christiano AM, Greenspan DS, Lee S, and Uitto J. Cloning of Human Type VII Colla‐
gen. Complete Primary Sequence of the Alpha 1(VII) Chain and Identification of In‐
tragenic Polymorphisms. J Biol Chem 1994;269(32) 20256-20262.
[17] Greenspan DS, Byers MG, Eddy RL, Hoffman GG, and Shows TB. Localization of the
Human Collagen Gene COL7A1 to 3p21.3 by Fluorescence in Situ Hybridization. Cy‐
togenet Cell Genet 1993;62(1) 35-36.
Gene Therapy - Tools and Potential Applications582
[18] Parente MG, Chung LC, Ryynanen J, Woodley DT, Wynn KC, Bauer EA, Mattei MG,
Chu ML, and Uitto J. Human Type VII Collagen: CDNA Cloning and Chromosomal
Mapping of the Gene. Proc Natl Acad Sci U S A 1991;88(16) 6931-6935.
[19] Kivirikko S, Li K, Christiano AM, and Uitto J. Cloning of Mouse Type VII Collagen
Reveals Evolutionary Conservation of Functional Protein Domains and Genomic Or‐
ganization. J Invest Dermatol 1996;106(6) 1300-1306.
[20] Ryynanen J, Sollberg S, Olsen DR, and Uitto J. Transforming Growth Factor-Beta Up-
Regulates Type VII Collagen Gene Expression in Normal and Transformed Epider‐
mal Keratinocytes in Culture. Biochem Biophys Res Commun 1991;180(2) 673-680.
[21] Vindevoghel L, Kon A, Lechleider RJ, Uitto J, Roberts AB, and Mauviel A. Smad-De‐
pendent Transcriptional Activation of Human Type VII Collagen Gene (COL7A1)
Promoter by Transforming Growth Factor-Beta. J Biol Chem 1998;273(21)
13053-13057.
[22] Ryynanen J, Sollberg S, Parente MG, Chung LC, Christiano AM, and Uitto J. Type VII
Collagen Gene Expression by Cultured Human Cells and in Fetal Skin. Abundant
MRNA and Protein Levels in Epidermal Keratinocytes. J Clin Invest 1992;89(1)
163-168.
[23] Colombo M, Brittingham RJ, Klement JF, Majsterek I, Birk DE, Uitto J, and Fertala A.
Procollagen VII Self-Assembly Depends on Site-Specific Interactions and Is Promoted
by Cleavage of the NC2 Domain With Procollagen C-Proteinase. Biochemistry
2003;42(39) 11434-11442.
[24] Chen M, Marinkovich MP, Veis A, Cai X, Rao CN, O'toole EA, and Woodley DT. In‐
teractions of the Amino-Terminal Noncollagenous (NC1) Domain of Type VII Colla‐
gen With Extracellular Matrix Components. A Potential Role in Epidermal-Dermal
Adherence in Human Skin. J Biol Chem 1997;272(23) 14516-14522.
[25] Brittingham R, Uitto J, and Fertala A. High-Affinity Binding of the NC1 Domain of
Collagen VII to Laminin 5 and Collagen IV. Biochem Biophys Res Commun
2006;343(3) 692-699.
[26] Ruoslahti E and Pierschbacher MD. New Perspectives in Cell Adhesion: RGD and In‐
tegrins. Science 1987;238(4826) 491-497.
[27] Dang N and Murrell DF. Mutation Analysis and Characterization of COL7A1 Muta‐
tions in Dystrophic Epidermolysis Bullosa. Exp Dermatol 2008;17(7) 553-568.
[28] Mecklenbeck S, Hammami-Hauasli N, Hopfner B, Schumann H, Kramer A, Kuster
W, and Bruckner-Tuderman L. Clustering of COL7A1 Mutations in Exon 73: Implica‐
tions for Mutation Analysis in Dystrophic Epidermolysis Bullosa. J Invest Dermatol
1999;112(3) 398-400.
[29] Whittock NV, Ashton GH, Mohammedi R, Mellerio JE, Mathew CG, Abbs SJ, Eady
RA, and McGrath JA. Comparative Mutation Detection Screening of the Type VII
Gene Therapy for the COL7A1 Gene
http://dx.doi.org/10.5772/51926
583
Collagen Gene (COL7A1) Using the Protein Truncation Test, Fluorescent Chemical
Cleavage of Mismatch, and Conformation Sensitive Gel Electrophoresis. J Invest Der‐
matol 1999;113(4) 673-686.
[30] Christiano AM, Anhalt G, Gibbons S, Bauer EA, and Uitto J. Premature Termination
Codons in the Type VII Collagen Gene (COL7A1) Underlie Severe, Mutilating Reces‐
sive Dystrophic Epidermolysis Bullosa. Genomics 1994;21(1) 160-168.
[31] Christiano AM, McGrath JA, Tan KC, and Uitto J. Glycine Substitutions in the Triple-
Helical Region of Type VII Collagen Result in a Spectrum of Dystrophic Epidermoly‐
sis Bullosa Phenotypes and Patterns of Inheritance. Am J Hum Genet 1996;58(4)
671-681.
[32] Bruckner-Tuderman L, Nilssen O, Zimmermann DR, Dours-Zimmermann MT, Ka‐
linke DU, Gedde-Dahl T, Jr., and Winberg JO. Immunohistochemical and Mutation
Analyses Demonstrate That Procollagen VII Is Processed to Collagen VII Through
Removal of the NC-2 Domain. J Cell Biol 1995;131(2) 551-559.
[33] Sawamura D, Goto M, Yasukawa K, Sato-Matsumura K, Nakamura H, Ito K, Naka‐
mura H, Tomita Y, and Shimizu H. Genetic Studies of 20 Japanese Families of Dys‐
trophic Epidermolysis Bullosa. J Hum Genet 2005;50(10) 543-546.
[34] Dunnill MG, McGrath JA, Richards AJ, Christiano AM, Uitto J, Pope FM, and Eady
RA. Clinicopathological Correlations of Compound Heterozygous COL7A1 Muta‐
tions in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol 1996;107(2)
171-177.
[35] Kern JS, Kohlhase J, Bruckner-Tuderman L, and Has C. Expanding the COL7A1 Mu‐
tation Database: Novel and Recurrent Mutations and Unusual Genotype-Phenotype
Constellations in 41 Patients With Dystrophic Epidermolysis Bullosa. J Invest Derma‐
tol 2006;126(5) 1006-1012.
[36] Christiano AM, McGrath JA, and Uitto J. Influence of the Second COL7A1 Mutation
in Determining the Phenotypic Severity of Recessive Dystrophic Epidermolysis Bul‐
losa. J Invest Dermatol 1996;106(4) 766-770.
[37] Hovnanian A, Rochat A, Bodemer C, Petit E, Rivers CA, Prost C, Fraitag S, Christi‐
ano AM, Uitto J, Lathrop M, Barrandon Y, and de Prost Y. Characterization of 18
New Mutations in COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Provides
Evidence for Distinct Molecular Mechanisms Underlying Defective Anchoring Fibril
Formation. Am J Hum Genet 1997;61(3) 599-610.
[38] Ryoo YW, Kim BC, and Lee KS. Characterization of Mutations of the Type VII Colla‐
gen Gene (COL7A1) in Recessive Dystrophic Epidermolysis Bullosa Mitis (M-RDEB)
From Three Korean Patients. J Dermatol Sci 2001;26(2) 125-132.
[39] Jarvikallio A, Pulkkinen L, and Uitto J. Molecular Basis of Dystrophic Epidermolysis
Bullosa: Mutations in the Type VII Collagen Gene (COL7A1). Hum Mutat 1997;10(5)
338-347.
Gene Therapy - Tools and Potential Applications584
[40] Sakuntabhai A, Hammami-Hauasli N, Bodemer C, Rochat A, Prost C, Barrandon Y,
de Prost Y, Lathrop M, Wojnarowska F, Bruckner-Tuderman L, and Hovnanian A.
Deletions Within COL7A1 Exons Distant From Consensus Splice Sites Alter Splicing
and Produce Shortened Polypeptides in Dominant Dystrophic Epidermolysis Bullo‐
sa. Am J Hum Genet 1998;63(3) 737-748.
[41] Cserhalmi-Friedman PB, McGrath JA, Mellerio JE, Romero R, Salas-Alanis JC, Paller
AS, Dietz HC, and Christiano AM. Restoration of Open Reading Frame Resulting
From Skipping of an Exon With an Internal Deletion in the COL7A1 Gene. Lab Invest
1998;78(12) 1483-1492.
[42] Posteraro P, Pascucci M, Colombi M, Barlati S, Giannetti A, Paradisi M, Mustonen A,
Zambruno G, and Castiglia D. Denaturing HPLC-Based Approach for Detection of
COL7A1 Gene Mutations Causing Dystrophic Epidermolysis Bullosa. Biochem Bio‐
phys Res Commun 2005;338(3) 1391-1401.
[43] Christiano AM, Fine JD, and Uitto J. Genetic Basis of Dominantly Inherited Transient
Bullous Dermolysis of the Newborn: a Splice Site Mutation in the Type VII Collagen
Gene. J Invest Dermatol 1997;109(6) 811-814.
[44] Jiang W, Bu D, Yang Y, and Zhu X. A Novel Splice Site Mutation in Collagen Type
VII Gene in a Chinese Family With Dominant Dystrophic Epidermolysis Bullosa Pru‐
riginosa. Acta Derm Venereol 2002;82(3) 187-191.
[45] Ito K, Sawamura D, Goto M, Nakamura H, Nishie W, Sakai K, Natsuga K, Shinkuma
S, Shibaki A, Uitto J, Denton CP, Nakajima O, Akiyama M, and Shimizu H. Keratino‐
cyte-/Fibroblast-Targeted Rescue of Col7a1-Disrupted Mice and Generation of an Ex‐
act Dystrophic Epidermolysis Bullosa Model Using a Human COL7A1 Mutation. Am
J Pathol 2009;175(6) 2508-2517.
[46] Fritsch A, Loeckermann S, Kern JS, Braun A, Bosl MR, Bley TA, Schumann H, von
Elverfeldt D, Paul D, Erlacher M, von Rautenfeld DB, Hausser I, Fassler R, and
Bruckner-Tuderman L. A Hypomorphic Mouse Model of Dystrophic Epidermolysis
Bullosa Reveals Mechanisms of Disease and Response to Fibroblast Therapy. Journal
of Clinical Investigation 2008;118(5) 1669-1679.
[47] Chen M, O'Toole EA, Muellenhoff M, Medina E, Kasahara N, and Woodley DT. De‐
velopment and Characterization of a Recombinant Truncated Type VII Collagen
"Minigene". Implication for Gene Therapy of Dystrophic Epidermolysis Bullosa. J Bi‐
ol Chem 2000;275(32) 24429-24435.
[48] Bruckner-Tuderman L. Hereditary Skin Diseases of Anchoring Fibrils. J Dermatol Sci
1999;20(2) 122-133.
[49] Bruckner-Tuderman L, Hopfner B, and Hammami-Hauasli N. Biology of Anchoring
Fibrils: Lessons From Dystrophic Epidermolysis Bullosa. Matrix Biol 1999;18(1) 43-54.
Gene Therapy for the COL7A1 Gene
http://dx.doi.org/10.5772/51926
585
[50] Woodley DT, Keene DR, Atha T, Huang Y, Lipman K, Li W, and Chen M. Injection of
Recombinant Human Type VII Collagen Restores Collagen Function in Dystrophic
Epidermolysis Bullosa. Nat Med 2004;10(7) 693-695.
[51] Woodley DT, Keene DR, Atha T, Huang Y, Ram R, Kasahara N, and Chen M. Intra‐
dermal Injection of Lentiviral Vectors Corrects Regenerated Human Dystrophic Epi‐
dermolysis Bullosa Skin Tissue in Vivo. Molecular Therapy 2004;10(2) 318-326.
[52] Sat E, Leung KH, Bruckner-Tuderman L, and Cheah KS. Tissue-Specific Expression
and Long-Term Deposition of Human Collagen VII in the Skin of Transgenic Mice:
Implications for Gene Therapy. Gene Ther 2000;7(19) 1631-1639.
[53] Mecklenbeck S, Compton SH, Mejia JE, Cervini R, Hovnanian A, Bruckner-Tuder‐
man L, and Barrandon Y. A Microinjected COL7A1-PAC Vector Restores Synthesis
of Intact Procollagen VII in a Dystrophic Epidermolysis Bullosa Keratinocyte Cell
Line. Hum Gene Ther 2002;13(13) 1655-1662.
[54] Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, and Khavari PA.
Stable Nonviral Genetic Correction of Inherited Human Skin Disease. Nat Med
2002;8(10) 1166-1170.
[55] Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O, Ortonne JP, Bruckner-Tuder‐
man L, and Meneguzzi G. Genetic Correction of Canine Dystrophic Epidermolysis
Bullosa Mediated by Retroviral Vectors. Hum Mol Genet 2003;12(15) 1897-1905.
[56] Gache Y, Baldeschi C, Del Rio M, Gagnoux-Palacios L, Larcher F, Lacour JP, and Me‐
neguzzi G. Construction of Skin Equivalents for Gene Therapy of Recessive Dystro‐
phic Epidermolysis Bullosa. Human Gene Therapy 2004;15(10) 921-933.
[57] Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon
PM, Mazurek C, and Woodley DT. Restoration of Type VII Collagen Expression and
Function in Dystrophic Epidermolysis Bullosa. Nat Genet 2002;32(4) 670-675.
[58] Goto M, Sawamura D, Ito K, Abe M, Nishie W, Sakai K, Shibaki A, Akiyama M, and
Shimizu H. Fibroblasts Show More Potential As Target Cells Than Keratinocytes in
COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa. J Invest Dermatol
2006;126(4) 766-772.
[59] Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M, and Shimizu H.
Targeted Skipping of a Single Exon Harboring a Premature Termination Codon Mu‐
tation: Implications and Potential for Gene Correction Therapy for Selective Dystro‐
phic Epidermolysis Bullosa Patients. Journal of Investigative Dermatology
2006;126(12) 2614-2620.
[60] Woodley DT, Krueger GG, Jorgensen CM, Fairley JA, Atha T, Huang Y, Chan L,
Keene DR, and Chen M. Normal and Gene-Corrected Dystrophic Epidermolysis Bul‐
losa Fibroblasts Alone Can Produce Type VII Collagen at the Basement Membrane
Zone. J Invest Dermatol 2003;121(5) 1021-1028.
Gene Therapy - Tools and Potential Applications586
[61] Wally V, Klausegger A, Koller U, Lochmuller H, Krause S, Wiche G, Mitchell LG,
Hintner H, and Bauer JW. 5' Trans-Splicing Repair of the PLEC1 Gene. J Invest Der‐
matol 2008;128(3) 568-574.
[62] Remington J, Wang XY, Hou YP, Zhou H, Burnett J, Muirhead T, Uitto J, Keene DR,
Woodley DT, and Chen M. Injection of Recombinant Human Type VII Collagen Cor‐
rects the Disease Phenotype in a Murine Model of Dystrophic Epidermolysis Bullosa.
Molecular Therapy 2009;17(1) 26-33.
[63] Titeux M, Pendaries V, Zanta-Boussif MA, Decha A, Pironon N, Tonasso L, Mejia JE,
Brice A, Danos O, and Hovnanian A. SIN Retroviral Vectors Expressing COL7A1 Un‐
der Human Promoters for Ex Vivo Gene Therapy of Recessive Dystrophic Epider‐
molysis Bullosa. Mol Ther 2010
[64] Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich PM, Lane AT, and Khavari
PA. Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin
Tissue. Hum Gene Ther 2010
[65] Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley
DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, and Tolar J. Bone
Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. N Engl J
Med 2010;363(7) 629-639.
[66] Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, Meneguzzi G,
Hintner H, and Bauer JW. Functional Correction of Type VII Collagen Expression in
Dystrophic Epidermolysis Bullosa. J Invest Dermatol 2011;131(1) 74-83.
[67] Horiuchi T and Aigaki T. Alternative Trans-Splicing: a Novel Mode of Pre-MRNA
Processing. Biol Cell 2006;98(2) 135-140.
[68] Mitchell LG and McGarrity GJ. Gene Therapy Progress and Prospects: Reprograming
Gene Expression by Trans-Splicing. Gene Ther 2005;12(20) 1477-1485.
[69] Wally V, Murauer EM, and Bauer JW. Spliceosome-Mediated Trans-Splicing: The
Therapeutic Cut and Paste. J Invest Dermatol 2012
[70] Wally V, Koller U, Murauer EM, Mayr E, Klausegger A, Hintner H, and Bauer JW.
Gene Therapy for Autosomal Dominant Diseases. Experimental Dermatology
2009;18(3) 283-283.
[71] Mansfield SG, Chao H, and Walsh CE. RNA Repair Using Spliceosome-Mediated
RNA Trans-Splicing. Trends Mol Med 2004;10(6) 263-268.
[72] Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML, and Crystal
RG. Trans-Splicing Repair of CD40 Ligand Deficiency Results in Naturally Regulated
Correction of a Mouse Model of Hyper-IgM X-Linked Immunodeficiency. Nat Med
2004;10(8) 835-841.
Gene Therapy for the COL7A1 Gene
http://dx.doi.org/10.5772/51926
587
[73] Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, and
Walsh CE. Phenotype Correction of Hemophilia A Mice by Spliceosome-Mediated
RNA Trans-Splicing. Nat Med 2003;9(8) 1015-1019.
[74] Puttaraju M, DiPasquale J, Baker CC, Mitchell LG, and Garcia-Blanco MA. Messen‐
ger RNA Repair and Restoration of Protein Function by Spliceosome-Mediated RNA
Trans-Splicing. Molecular Therapy 2001;4(2) 105-114.
[75] Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG, and En‐
gelhardt JF. Spliceosome-Mediated RNA Trans-Splicing With Recombinant Adeno-
Associated Virus Partially Restores Cystic Fibrosis Transmembrane Conductance
Regulator Function to Polarized Human Cystic Fibrosis Airway Epithelial Cells.
Hum Gene Ther 2005;16(9) 1116-1123.
[76] Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Yee C, Klausegger A, Hintner H,
and Bauer JW. Development of Spliceosome-Mediated RNA Trans-Splicing (SMaRT
(TM)) for the Correction of Inherited Skin Diseases. Experimental Dermatology
2003;12(1) 37-46.
[77] Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, Grover AC, Hutton M, Yu Q,
Zhou J, Anderton BH, and Gallo JM. Reprogramming of Tau Alternative Splicing by
Spliceosome-Mediated RNA Trans-Splicing: Implications for Tauopathies. Proc Natl
Acad Sci U S A 2005;102(43) 15659-15664.
[78] Zayed H, Xia L, Yerich A, Yant SR, Kay MA, Puttaraju M, McGarrity GJ, Wiest DL,
McIvor RS, Tolar J, and Blazar BR. Correction of DNA Protein Kinase Deficiency by
Spliceosome-Mediated RNA Trans-Splicing and Sleeping Beauty Transposon Deliv‐
ery. Mol Ther 2007;15(7) 1273-1279.
[79] Chen HY, Kathirvel P, Yee WC, and Lai PS. Correction of Dystrophia Myotonica
Type 1 Pre-MRNA Transcripts by Artificial Trans-Splicing. Gene Ther 2009;16(2)
211-217.
[80] Coady TH and Lorson CL. Trans-Splicing-Mediated Improvement in a Severe Mouse
Model of Spinal Muscular Atrophy. J Neurosci 2010;30(1) 126-130.
[81] Wang J, Mansfield SG, Cote CA, Du Jiang P, Weng K, Amar MJA, Brewer BH, Rema‐
ley AT, McGarrity GJ, Garcia-Blanco MA, and Puttaraju M. Trans-Splicing Into High‐
ly Abundant Albumin Transcripts for Production of Therapeutic Proteins In Vivo.
Molecular Therapy 2009;17(2) 343-351.
[82] Gruber C, Gratz IK, Murauer EM, Mayr E, Koller U, Bruckner-Tuderman L, Mene‐
guzzi G, Hintner H, and Bauer JW. Spliceosome-Mediated RNA Trans-Splicing Facil‐
itates Targeted Delivery of Suicide Genes to Cancer Cells. Mol Cancer Ther 2011
[83] Mansfield SG, Clark RH, Puttaraju M, Kole J, Cohn JA, Mitchell LG, and Garcia-Blan‐
co MA. 5' Exon Replacement and Repair by Spliceosome-Mediated RNA Trans-Splic‐
ing. RNA 2003;9(10) 1290-1297.
Gene Therapy - Tools and Potential Applications588
[84] Kierlin-Duncan MN and Sullenger BA. Using 5'-PTMs to Repair Mutant Beta-Globin
Transcripts. RNA 2007
[85] Wally V, Brunner M, Lettner T, Wagner M, Koller U, Trost A, Murauer EM, Hainzl S,
Hintner H, and Bauer JW. K14 MRNA Reprogramming for Dominant Epidermolysis
Bullosa Simplex. Hum Mol Genet 2010;19(23) 4715-4725.
[86] Rindt H, Yen PF, Thebeau CN, Peterson TS, Weisman GA, and Lorson CL. Replace‐
ment of Huntingtin Exon 1 by Trans-Splicing. Cell Mol Life Sci 2012
[87] Lorain S, Peccate C, Le Hir M, and Garcia L. Exon Exchange Approach to Repair
Duchenne Dystrophin Transcripts. PLoS One 2010;5(5) e10894-
[88] Koller U, Wally V, Mitchell LG, Klausegger A, Murauer EM, Mayr E, Gruber C,
Hainzl S, Hintner H, and Bauer JW. A Novel Screening System Improves Genetic
Correction by Internal Exon Replacement. Nucleic Acids Res 2011;39(16) e108-
[89] Wally V, Koller U, Bauer JW. High-Throughput Screening for Highly Functional
RNA-Trans-Splicing Molecules: Correction of Plectin in Epidermolysis Bullosa Sim‐
plex. In: Plaseska-Karanfilska D (ed.) Human Genetic Diseases. Rijeka: InTech; 2011.
p223-240 Available from: http://www.intechopen.com/books/human-genetic-diseases
(Accessed 3 October 2011)
Gene Therapy for the COL7A1 Gene
http://dx.doi.org/10.5772/51926
589

